OPEN

Three-row versus two-row circular staplers for leftsided colorectal anastomosis: a propensity scorematched analysis of the iCral 2 and 3 prospective cohorts

Marco Catarci, MD^{a,b,*}, Stefano Guadagni, MD^c, Francesco Masedu, PhD^d, Giacomo Ruffo, MD^e, Massimo G. Viola, MD^f, Felice Borghi, MD^{g,h}, Gianandrea Baldazzi, MD^{i,j}, Marco Scatizzi, MD^k, on behalf of the Italian ColoRectal Anastomotic Leakage (iCral) study group

Background: Since most anastomoses after left-sided colorectal resections are performed with a circular stapler, any technological change in stapling devices may influence the incidence of anastomotic adverse events. The aim of the present study was to analyze the effect of a three-row circular stapler on anastomotic leakage and related morbidity after left-sided colorectal resections. **Materials and methods:** A circular stapled anastomosis was performed in 4255 (50.9%) out of 8359 patients enrolled in two prospective multicenter studies in Italy, and, after exclusion criteria to reduce heterogeneity, 2799 (65.8%) cases were retrospectively analyzed through a 1:1 propensity score-matching model including 20 covariates relative to patient characteristics, to surgery and to perioperative management. Two well-balanced groups of 425 patients each were obtained: group (A) – true population of interest, anastomosis performed with a three-row circular stapler; group (B) – control population, anastomosis performed with a two-row circular stapler. The target of inferences was the average treatment effect in the treated (ATT). The primary endpoints were overall and major anastomotic leakage and overall anastomotic bleeding; the secondary endpoints were overall and major morbidity and mortality rates. The results of multiple logistic regression analyses for the outcomes, including the 20 covariates selected for matching, were presented as odds ratios (OR) and 95% confidence intervals (95% CI).

Results: Group A versus group B showed a significantly lower risk of overall anastomotic leakage (2.1 vs. 6.1%; OR 0.33; 95% CI 0.15–0.73; P = 0.006), major anastomotic leakage (2.1 vs. 5.2%; OR 0.39; 95% CI 0.17–0.87; P = 0.022), and major morbidity (3.5 vs. 6.6% events; OR 0.47; 95% CI 0.24–0.91; P = 0.026).

Conclusion: The use of three-row circular staplers independently reduced the risk of anastomotic leakage and related morbidity after left-sided colorectal resection. Twenty-five patients were required to avoid one leakage.

Keywords: anastomotic leakage, circular staplers, colorectal surgery

Introduction

The last decade has witnessed a significant evolution in colorectal surgery, due to the diffusion of minimally invasive approaches (either laparoscopic or robotic) and the implementation of enhanced recovery pathways (ERP)^[1], allowing optimal oncological, physiological, and cosmetic results associated with shorter

postoperative stay^[2]. However, early anastomotic adverse events, such as leakage (AL) and bleeding (AB), remain the Achille's heel of any colorectal anastomosis, leading to prolonged post-operative stay, increased costs, risk of reoperation, and permanent colostomy, together with an increase in overall morbidity and mortality rates^[3,4]. Furthermore, AL has been shown to

Published online 17 May 2023

^aGeneral Surgery Unit, Sandro Pertini Hospital, ASL Roma 2, Rome, ^bGeneral Surgery Unit, "C.&G. Mazzoni" Hospital, Ascoli Piceno, ^cGeneral Surgery Unit, University of L'Aquila, L'Aquila, ^dDepartment of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, ^eGeneral Surgery Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella (VR), ^fGeneral Surgery Unit, Cardinale G. Panico Hospital, Tricase (LE), ^gOncologic Surgery Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), ^hGeneral & Oncologic Surgery Unit, Department of Surgery, Santa Croce e Carle Hospital, Cuneo, ⁱGeneral Surgery Unit, ASST Ovest Milanese, Legnano (MI), ^jGeneral Surgery Unit, ASST Nord Milano, Sesto San Giovanni (MI) and ^kGeneral Surgery Unit, Santa Maria Annunziata & Serristori Hospital, Firenze, Italy

M.C. is study group coordinator.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

^{*}Corresponding author. Address: Ospedale "Sandro Pertini", ASL Roma 2, Via dei Monti Tiburtini, 385, 00157 Roma, Italy. Tel.: + 39 329 861 0040. E-mail: marco. catarci@aslroma2.it (M. Catarci).

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

International Journal of Surgery (2023) 109:2312-2323

Received 8 March 2023; Accepted 8 May 2023

http://dx.doi.org/10.1097/JS9.000000000000480

affect long-term outcomes being associated with a higher risk of recurrence and shortened survival in colorectal cancer^[5].

Nearly 50 years have passed since the first description of mechanical circular staplers (CS) to facilitate colorectal anastomosis^[6], and the double-stapling technique for colorectal end-to-end anastomosis has rapidly become a standard practice that is still widely used today^[7], having demonstrated safety and efficacy equivalent to the hand-sewn anastomosis with the advantages of shorter anastomotic time, less contamination, and greater reproducibility^[8,9].

Beyond well-known patient-related, disease-related, and procedure-related risk factors^[10], successful healing of any anastomosis relies on an effective blood supply and micro-perfusion of the anastomotic tissue and on the mechanical strength of the newly formed anastomosis^[11]. Consequently, any technological improvement in CS may represent a target for AL risk reduction, and during the last 5 years, two significant developments have been commercially available for this purpose. The powered tworow circular stapler (Ethicon, Somerville, New Jersey, USA) decrease the force needed for firing, improving stability at the anastomotic site, reduces the compressive forces on tissues and their slippage, and utilizes two rows of staples with threedimensional architecture^[12]. The three-row circular stapler (Covidien, New Haven, Connecticut, USA) is based on three circular rows of conventional, B-shaped staples, varying in height: the staples of the inner row, closest to the anastomotic lumen, have the shortest height to provide the greatest occlusion and barrier to leak and to bleed, while the second and third rows, each with incrementally longer staples' height, contribute strength to the closure line, enhancing both tissue micro-perfusion^[13] and pressure resistance^[14]. Despite several animal models and clinical and artificial intelligence studies^[14-17], the effectiveness of the three-row CS in reducing the AL risk has not been fully examined or demonstrated mainly because of the small sample size, small number of considered conditioning variables, and lack of comparison with two-row CS of different producers. Although highly advisable^[18], administrative, economic, and ethical reasons have hindered, to date, a randomized clinical trial on this issue, and the Italian ColoRectal Anastomotic Leakage (iCral) study group decided to estimate the treatment effects of the threerow CS on data derived from two prospective open-label observational multicenter studies^[19,20].

Material and methods

Study design

This was a retrospective analysis of a prospective database of patients who underwent colorectal resection and anastomosis for malignant and benign diseases. The aim of the present study was to evaluate the effectiveness of the three-row CS in reducing the risk of early adverse events in a population of patients who underwent left colectomy and/or anterior resection with end-to-end stapled colorectal anastomosis, compared to a control population in which a two-row CS was used. Propensity score-matching analysis (PSMA) was used to adjust for heterogeneity between the two groups.

Patient population and data collection

Patients were enrolled in two consecutive studies: iCral2^[19] and iCral3^[20]. Both studies, designed to investigate the effects of ERP

HIGHLIGHTS

- Since most anastomoses after left-sided colorectal resections are performed with a circular stapler, any technological advancement in stapling devices may influence the incidence of anastomotic leakage and related morbidity.
- In this propensity score-matched analysis, including 850 left-sided colorectal resections derived from two prospective multicenter studies, the use of a three staple row versus a two staple row circular stapler determined a 4.0% (2.1 vs. 6.1%) absolute risk reduction of anastomotic leakage.

adherence rates on several outcomes, were based on prospective enrollment on a voluntary basis in Italy, carried out from January 2019 to June 2020 in 38 surgical centers (iCral2) and from October 2020 to September 2021 in 76 surgical centers (iCral3). A total of 78 centers were involved in one (42 centers) or both (36 centers) of the studies. All patients who underwent colorectal resection with anastomosis (laparoscopic, robotic, open, or converted approach, including planned Hartmann's reversals) were assessed according to explicit inclusion/exclusion criteria shared by both studies. Inclusion criteria were: American Society of Anesthesiologists (ASA) class I, II, or III; elective or delayed urgency setting (defined >48 h from admission in iCral2 and >24 h from admission in iCral3); patient's written informed consent for inclusion in the study and processing of sensitive data. Exclusion criteria were: pregnancy; hyperthermic chemotherapy (HIPEC) for carcinomatosis; incomplete data. The iCral2 study excluded patients with a protective stoma proximal to the anastomosis; conversely, these cases were included in the iCral3 study.

Each center was defined as a high volume (\geq 4) or low volume (<4) according to the median number of enrolled cases per month. All data of the included patients were prospectively uploaded to a web-based database via an electronic case report form, specifically designed for both studies and protected by access credentials for each center/investigator. Continuous and discrete variables related to biometric data, patient-related risk factors, indications and types of surgical procedures, adherence to ERP items, and outcomes were recorded in all cases. When anastomosis was performed with a CS, complete data regarding the manufacturer, model, and diameter were recorded. Quality control of the data for consistency, plausibility, and completeness was performed on each record by local investigators and subsequently validated by the study coordinator, resolving any discrepancies through strict cooperation. During the perioperative period, patients were examined daily by local investigators, who recorded and graded any adverse event and were free to decide on complementary imaging and any further action according to their local criteria.

Both studies were conducted in accordance with the Declaration of Helsinki and the guidelines for good clinical practice E6 (R2). The study protocols were approved by the ethics committee of the coordinating center and registered at ClinicalTrials.gov. Subsequently, all other centers were authorized to participate in their local ethics committees. Both studies followed the Strengthening the Reporting of Cohort Studies in Surgery (STROCSS) guidelines^[21]. Individual participant-level anonymized datasets were made available for both studies upon reasonable request by contacting the study coordinator.

To control for data heterogeneity derived from several treatment confounders, PSMA included 2799 patients (65.8%) out of 4255 cases in which anastomosis was performed using a CS, based on explicit exclusion criteria: any resection different from left colectomy or anterior resection, neo-adjuvant therapy, any anastomosis different form end-to-end, any anastomosis located less than 5 cm from the external anal verge, any anastomosis performed with a 25 mm diameter CS, and any anastomosis protected by a proximal stoma (Fig. 1). The variables and outcomes recorded for the study population are shown in Table 1. To optimize the effectiveness of the PSMA by reducing the number of unmatched cases, continuous variables were categorized according to their median values.

Adverse events

All the enrolled patients were followed-up for 8 weeks after surgery, recording and grading any adverse event according to Clavien–Dindo^[23] and the Japanese Clinical Oncology Group (JCOG) extended criteria^[24], as well as any unplanned readmission, reoperation, or death, calculated at 60 days after surgery. AL was defined according to the international consensus^[25,] and AB was defined as persistent rectal bleeding associated with at least a 20 g/l decrease in hemoglobin concentration^[26]. Adverse events and their grading are reported in Table 2.

Outcomes

The primary endpoints were overall AL (any AL), major AL (any AL grade > II), and AB, and the secondary endpoints were overall morbidity (any adverse event), major morbidity (any adverse event grade > II), and mortality (any death).

Statistical analysis

No missing data were observed in the database of 2799 patients. A propensity score-matching model^[27] was used for analysis (Fig. 1). Based on its original theory^[28], the propensity score is a variable that groups several covariates and represents the conditional probability of receiving a protective treatment effect on the outcomes using or not using the treatment variable. The theory requires the following assumptions: no unmeasured confounding variable; the propensity score should not be exactly 0 or 1; the treatment should be well-defined and homogeneous; sufficient overlap in subgroups of covariates; and balance model specifications. Adjusted logistic regression was used to estimate the propensity scores of the treatment and control groups. Based on the conditioning categorical variables selected, each patient was assigned a propensity score estimated by the standardized mean difference (a standardized mean difference less than 0.1 typically indicates a negligible difference between the means of the groups). The treatment (exposure) variable was end-to-end anastomosis performed using the three-row CS, and 20 confounding variables (covariates), potentially affecting the treatment were selected: age, sex, American Society of Anesthesiologists (ASA) class, body mass index (BMI), diabetes, chronic renal failure, chronic liver disease, surgery for malignancy, left colectomy as a type of resection, operation length (minutes), center volume, open surgery, intracorporeal or extracorporeal anastomosis, the diameter of the circular stapler, preoperative blood transfusion(s), intraoperative and/or postoperative blood transfusion(s), and overall,




Figure 1. Study flowchart according to the Strengthening the Reporting of Cohort Studies in Surgery (STROCSS) guidelines^[21] and to the Reporting and Guidelines in Propensity Score Analysis^[22]. iCral, Italian ColoRectal Anastomotic Leakage study group; ERP, enhanced recovery pathway.

preoperative, intraoperative, and postoperative ERP items adherence rates. No outcome variable was included^[29].

As the balance is the main goal of PSMA, the analysis was performed using the software 'R' (Version 4.2.2, The R Foundation for Statistical Computing, Vienna, Austria, 2022) with the following specifications: seed 100 for the reproducibility of the analysis; method for distance metric = nearest, distance = logit, caliper = 0.1, replace = false (without sampling replacement),

 Table 1

 Descriptive analysis of the study population variables.

Variable	Pattern	Number	%
Age (year)	< 65.2	1399	49.9
	≥65.2	1400	50.1
Sex	Male	1363	48.7
	Female	1436	51.3
ASA class	I–II	2053	73.3
	III 	746	26.7
Body mass index (kg/m ²)	≤ 25.0	1389	49.6
	> 25.0	1410	50.4
Diabetes	Yes	298	10.6
Obversio vessel failure	No	2501	89.4
Chronic renal failure	Yes No	77 2722	2.8 97.2
Chronic liver disease	Yes	2722 22	97.2 0.8
	No	2777	99.2
Surgery for malignancy	Yes	1684	60.2
ourgory for manghanoy	No	1115	39.8
	Diverticular disease	758	00.0
	Endometriosis	246	
	Polyps	74	
	Inflammatory bowel disease	6	
	Other	31	
Type of resection	Anterior resection	894	31.9
	Left colectomy	1905	68.1
Type of circular stapler	Three-row	488	17.4
	Two-row	2311	82.6
	Covidien – DST EEA	938	
	Ethicon ECHELON Powered Stapler	172	
	- CDHP		
	Ethicon Circular Stapler – ECS	122	
	Ethicon Circular Stapler – CDH	764	
	Touchstone Endoscopic Circular	128	
	Stapler – ECSC	100	
	Touchstone Circular Stapler – CSC Other	139 48	
Diameter of the circular stapler	< 30 mm	1929	68.9
	≥ 30 mm	870	31.1
Anastomosis	Intracorporeal	2457	87.8
	Extracorporeal	342	12.2
Operation length (minutes)	≤ 180	1268	45.3
	_ > 180	1531	54.7
Center volume	Low; <4 enrolled cases/month	676	24.2
	High; \geq 4 enrolled cases/month	2123	75.8
Open surgery	Yes	154	5.5
	No	2645	94.5
	Laparoscopic	2288	
	Robotic	249	
	Converted	108	
Preoperative blood transfusion(s)		53	1.9
Intraoperative/postoperative blood		100	3.6
transfusion(s)		1000	40 1
Overall ERP adherence (%)	≤75.0 > 75.0	1290	46.1
Nutritional screening	> 75.0	1509 1917	53.9 68.5
Prehabilitation		977	34.9
Counseling		977 1770	54.9 63.2
Immune enhancing nutrition		769	27.5
Antithrombotic prophylaxis		2611	93.3
Antibiotic prophylaxis		2643	94.4
No mechanical bowel preparation		1623	58.0
Preoperative carbohydrates load		1533	54.8
Preoperative ERP adherence (%)	≤57.1	1029	36.8
	> 57.1	1770	63.2
	2 01.1		00.2

(Continued)

Variable	Pattern	Number	%
No preanesthesia		1970	70.4
Standard anesthesia protocol		2088	74.6
Normothermia		2466	88.1
Goal-directed or restrictive fluid therapy		1994	71.2
Postoperative nausea/vomit prophylaxis		2340	83.6
Multimodal analgesia		2433	86.9
No nasogastric tube		2483	88.7
Minimally invasive surgery		2645	94.5
No drains		861	30.8
Intraoperative ERP adherence (%)	≤88.9	2247	80.3
	> 88.9	552	19.7
Urinary catheter <24-48 h		2053	73.3
Early mobilization		1628	58.2
Early oral feeding		1672	59.7
Predischarge check		2179	77.8
Postoperative ERP adherence (%)	≤75.0	1141	40.8
	> 75.0	1658	59.2
Overall morbidity		731	26.1
Major morbidity		191	6.8
Anastomotic leakage		140	5.0
Major anastomotic leakage		111	4.0
Anastomotic bleeding		102	3.6
Mortality		22	0.8

ASA, American Society of Anesthesiologists; ERP, enhanced recovery pathway.

ratio = 1; adjusted logistic regression to estimate the association between the exposure/treatment variable and the outcomes. The following R libraries/programs have been used: 'matchit', 'glm',

Table 2

Adverse events and grading in the study population.

		Clavie	en–Din	do and	I JCOG	grade	l
Adverse event	I	II	Illa	IIIb	IVa	IVb	Total
Anastomotic leakage	9	20	6	94	6	5	140
Superficial surgical site infections	25	34	0	0	0	0	59
Abdominal collection/abscess	2	14	14	1	0	0	31
Small bowel obstruction	1	10	1	15	0	0	27
Anastomotic bleeding	45	19	29	6	3	0	102
Abdominal bleeding	3	6	6	12	0	0	27
Small bowel perforation	0	0	0	3	0	0	3
Deep wound dehiscence	0	3	0	2	0	0	5
Trocar/wound site bleeding	8	1	1	1	0	0	11
Anemia	7	59	0	0	0	0	66
Paralytic ileus	33	36	0	0	0	0	69
Fever	34	59	0	0	0	0	93
DVT/pulmonary embolism	0	4	0	0	1	0	5
Neurologic	7	4	0	1	0	1	13
Pneumonia and pulmonary failure	8	33	9	0	7	5	62
Urinary retention	27	25	0	0	0	0	52
Urinary tract infection	2	3	0	0	0	0	5
Acute renal failure	3	2	0	0	1	0	6
Acute mesenteric ischemia	0	0	0	3	0	0	3
Acute peptic ulcer/erosive gastritis	0	0	2	0	0	0	2
Other	51	40	9	5	1	1	107
Total	265	372	77	143	19	12	888

DVT, deep venous thrombosis; JCOG, Japanese Clinical Oncology Group.

		21	- II
_	-	• 1 I	

Details of the circular staplers used for end-to-end colorectal anastomosis in the treatment and control groups.

	Treatment Group (A):	three-row CS			Control Group (B): t	wo-row CS	
Producer	Model	Number	%	Producer	Model	Number	%
Covidien	TRIEEA28MT	157	37.0	Ethicon	CDH29A	68	16.0
	TRIEEA28XT	19	4.5		ECS29A	9	2.1
	TRIEEA31MT	216	50.8		CDH33A	35	8.2
	TRIEEA31XT	30	7.5		CDH29P	14	3.3
	TRIEEA33MT	3	0.7		CDH31P	26	6.1
				Covidien	DSTEEA28	49	11.5
					DSTEEA28XL	7	1.6
					DSTEEA31	105	24.7
					DSTEEA31XL	31	7.3
					DSTEEA33	5	1.2
					DSTEEA33XL	42	9.9
				Touchstone	CSC29A	14	3.3
					ECSC29	12	2.8
					CSC33A	1	0.2
				ECSC33	1	0.2	
				Other	Not available	6	1.4

CS, circular stapler.

'publish', 'Tablone', 'Plot', and 'cobalt'^[30]. Balance in the matched groups was assessed by calculating the standardized mean difference (SMD) and general variance ratio (a variance ratio close to 1 indicates that variances are equal in the two groups). For outcome modeling, an adjusted logistic regression based on the use of the three-row CS as the treatment variable and on the same 20 covariates selected for the PSMA was performed, presenting odds ratios (OR) and 95% confidence intervals (95% CI). The eventual effect of any unobserved confounder was tested through a sensitivity analysis^[31], using the library 'SensitivityR5' of the software 'R' (Version 4.2.2, The R Foundation for Statistical Computing, Vienna, Austria, 2022) and presenting the Γ values (each 0.1 increment of Γ values representing a 10%-odds of differential assignment to treatment due to any unobserved variable).

Results

After propensity score-matching, 1949 patients were excluded (63 treated with the three-row CS and 1886 with the two-row CS), and two groups of 425 patients each were generated: group A (treatment, true population of interest), using the new threerow CS, and group B (control population), using a two-row CS. This population of 850 patients includes data deriving from 62 (79.5%) of the original 78 centers: group A included data deriving from 45 (57.7%) centers, and group B from 54 (69.2%) centers. The details of the CS models used in both groups are shown in Table 3. A good balance between the two groups was achieved (Table 4 and Fig. 2), with a model variance ratio of 1.049. AL diagnosis was established by intravenous contrast CT scan in 57 (40.7%), clinical criteria in 49 (35.0%), endoluminal contrast CT scan in 26 (18.6%), endoluminal contrast enema in 4 (2.8%), and gross findings at reoperation in the remaining four cases (2.8%).

The results of the adjusted logistic regression and sensitivity analyses are reported in Table 5 for the primary endpoints and Table 6 for the secondary endpoints.

Group A versus group B showed a significantly lower risk of overall anastomotic leakage [9 (2.1%) vs. 26 (6.1%) events; OR

0.33; 95% CI 0.15–0.73; P = 0.006] and major anastomotic leakage [9 (2.1%) vs. 22 (5.2%) events; OR 0.39; 95% CI 0.17–0.87; P = 0.022]. Concerning the risk of AB, no difference was recorded between the two groups (Table 5), whereas it was significantly lower for adherence to preoperative ERP items above its median value [4/573 (0.7%) vs. 8/277 (2.9%) events; OR 0.10; 95% CI 0.02–0.48, P = 0.004].

Regarding secondary endpoints, a significantly lower risk of major morbidity was recorded in group A than in group B [15 (3.5%) vs. 28 (6.6%) events; OR 0.47; 95% CI 0.24-0.91; P = 0.026], while no significant difference between the two groups was recorded in terms of the risk of overall morbidity and mortality (Table 6). The use of CS diameter at least 30 mm versus less than 30 mm significantly reduced the risk of major morbidity [14/495 (2.8%) vs. 29/355 (8.2%) events; OR 0.33; 95% CI 0.16–0.65; P = 0.002 and the risk of overall morbidity [95/495 (19.2%) vs. 93/355 (26.2%) events; OR 0.66; 95% CI 0.47–0.94, P = 0.02]. The sensitivity analysis showed $\Gamma = 1.5$ for overall anastomotic leakage, meaning that 50% of patients should have been treated with a two-row CS instead of a threerow CS because of unknown and/or unmeasured confounding variables to alter the result (association of three-row CS use and lower risk of anastomotic leakage) or to lose statistical significance (30% for major anastomotic leakage and 20% for major morbidity).

Discussion

To our best knowledge, this is the first clinical study based on a large, prospective, multicenter database, comparing threerow CS with several two-row CS of different producers, evaluating the risk of early anastomotic adverse events after left-sided colorectal resection for malignant and benign diseases with stapled end-to-end colorectal anastomosis. The use of the three-row CS significantly and independently reduced AL and major morbidity rates. From a practical point of view, the use of a three-row CS determined a 4% absolute risk reduction for overall AL (3% for major AL and major

Variables distribution in treatment and control groups before and after propensity score-matching.

Age <th colspan="2"></th> <th>Before p</th> <th>propensity score-mate</th> <th>hing</th> <th colspan="5">After propensity score-matching</th>			Before p	propensity score-mate	hing	After propensity score-matching				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Variable	Pattern			^a P	SMD			^a P	SMD
Sox Main 266 1097 0.01 0.74 271 274 0.01 0.01 ASA class I-II 321 1732 0.001 1.23 274 287 0.75 Body mass index ≤25 kg/m² 215 1174 0.001 0.76 242 250 0.71 Chronic resul failure Yes 60 238 0.001 1.73 306 0.003 - 0.001 0.76 242 250 0.013 - 0.001 1.76 242 250 0.011 0.76 0.001 1.73 306 0.003 - 0.001 0.78 242 250 0.001 1.70 141 1.10 0.00 0.001 <td>Age</td> <td>< 65.2 years</td> <td>198</td> <td>1201</td> <td>0.001</td> <td>0.91</td> <td>160</td> <td>170</td> <td>0.58</td> <td>0.03</td>	Age	< 65.2 years	198	1201	0.001	0.91	160	170	0.58	0.03
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		\geq 65.2 years	290	1110	0.001	- 0.25	265	255	0.64	- 0.03
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Sex	Male	266	1097	0.001	0.74	237	234	0.91	- 0.008
		Female	222	1214	0.001	0.89	188	191	0.91	0.008
Body mass index ≤ 25 kg/m ² 215 1174 0.001 0.86 183 175 0.08 - Dabetes Yes 60 238 0.001 0.76 242 250 0.03 - Dabetes Yes 60 238 0.001 1.47 375 385 0.66 Chronic renal failure Yes 19 58 0.001 1.21 1.41 1.40 1.00 Chronic fiver disease Yes 7 15 0.13 0.05 5 4 1.00 Surgery for malignancy Yes 319 1365 0.001 0.74 141 148 0.70 Surgery for malignancy Yes 319 1365 0.001 0.74 141 148 0.77 0.76 Left colectomy 391 1514 0.001 0.33 351 0.40 0.22 249 246 0.92 2.30 0.33 .51 0.40 0.22 224 2	ASA class	I–II	321	1732	0.001	1.23	274	267	0.75	- 0.02
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			167	579	0.001	0.44	151	158	0.71	0.02
Diabetes Yes 60 238 0.001 0.29 50 40 0.33 = No 448 2073 0.001 1.47 375 385 0.66 Chronic liver disease Yes 19 58 0.001 1.66 411 414 1.00 Chronic liver disease Yes 7 15 0.13 0.05 5 4 1.00 Surgery for malignancy Yes 319 1365 0.001 0.73 9.2 74 0.76 Type of resection Anterior resection 97 797 0.001 0.73 9.2 74 0.66 Laft colectomy 301 1514 0.001 0.73 9.2 74 0.66 Salo mm 177 1.752 0.001 1.47 176 179 0.901 Lanct colectomy 301 1514 0.001 0.72 282 0.83 . Anastomosis Intracoporeal 470	Body mass index	\leq 25 kg/m ²			0.001				0.68	- 0.02
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		> 25 kg/m ²			0.001				0.71	0.02
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Diabetes	Yes	60	238	0.001	0.29	50	40	0.33	- 0.05
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		No	428		0.001	1.47	375	385	0.66	0.02
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Chronic renal failure	Yes	19	58	0.001	0.12	14	14	1.00	0.00
No48122960.011.704204211.00Surgery for malignancyYes31913650.0010.892842770.76-No1699460.0010.741411480.70-Type of resectionAnterior resection977970.0010.7392740.16-Diameter of CS<30 mm		No	469		0.001		411	411	1.00	0.00
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Chronic liver disease							4	1.00	- 0.02
No 169 946 0.01 0.74 141 148 0.70 Type of resection Anterior resection 97 797 0.001 0.73 92 74 0.16 - Diameter of CS < 30 mm		No						Two-row CS 170 0 170 0 255 0 234 0 191 0 267 0 158 0 175 250 40 0 385 0 40 385 14 11 4 217 2777 0 148 0 74 351 79 246 402 0 233 0 217 0 208 0 339 14 10 415 11 11 114 0 411 0 326 0 328 0 339 0 341 0 411 0 351		0.002
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Surgery for malignancy				0.001				0.76	- 0.02
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		No							vo-row CS ^{3}P SI 170 0.58 0 255 0.64 -0 234 0.91 -0 191 0.91 0 267 0.75 -0 158 0.71 0 175 0.68 -0 250 0.71 0 40 0.33 -0 385 0.66 0 14 1.00 0 411 1.00 0 421 1.00 0 246 0.92 -0 402 0.85 -0 233 0.53 0 217 0.43 0 217 0.43 0 208 0.44 -0 339 0.62 -0 14 0.84 0 411 0.96 -0 10 0.67 -0 339 0.62 -0	0.02
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Type of resection	Anterior resection							0.16	- 0.07
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			391	1514	0.001	0.93	333	351	0.40	0.04
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Diameter of CS	< 30 mm			0.001		176		0.90	0.01
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		≥30 mm	311	559	0.001	0.25	249	246	0.92	- 0.01
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Anastomosis	Intracorporeal			0.001				0.85	- 0.01
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Extracorporeal	18	324	0.001	0.47	18	23	0.53	0.04
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Operation length	≤ 180 min	248	1020	0.001	0.70	202	217	0.43	0.04
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		> 180 min	240	1291	0.001	0.93	223	208	0.44	-0.04
Open surgery Yes 13 141 0.00 0.28 12 14 0.84 No 475 2170 0.001 1.53 413 411 0.96 - Preoperative BT Yes 17 36 0.01 0.07 13 10 0.67 - Intraoperative and postoperative BT Yes 14 86 0.001 0.20 12 11 1.00 - No 474 2225 0.001 1.61 413 414 1.00 - Overall ERP adherence <75.0%	Center volume	Low	76	600	0.001	0.60	75	86	0.41	0.04
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		High	412	1711	0.001	1.09	350	339	0.62	- 0.03
Preoperative BT Yes 17 36 0.01 0.07 13 10 0.67 - No 471 2275 0.001 1.69 412 415 0.92 Intraoperative and postoperative BT Yes 14 86 0.001 0.20 12 11 1.00 - Overall ERP adherence 75.0% 68 1222 0.001 1.61 413 414 1.00 - Overall ERP adherence 75.0% 68 1222 0.001 0.56 358 358 1.00 - Preoperative ERP adherence 57.1% 67 962 0.001 0.76 359 365 0.81 - Intraoperative ERP adherence 57.1% 421 1349 0.001 0.76 359 365 0.81 - Postoperative ERP adherence 75.0% 87 1054 0.001 0.26 131 141 0.50 -	Open surgery	Yes	13	141	0.001	0.28	12	14	0.84	0.02
No 471 2275 0.001 1.69 412 415 0.92 Intraoperative and postoperative BT Yes 14 86 0.001 0.20 12 11 1.00 - Overall ERP adherence ≤75.0% 68 1222 0.001 1.61 413 414 1.00 Preoperative ERP adherence ≤57.1% 67 962 0.001 0.91 66 60 0.64 - Softward ERP adherence ≤57.1% 67 962 0.001 0.76 359 365 0.81 Intraoperative ERP adherence ≤57.1% 67 962 0.001 0.76 359 365 0.81 Intraoperative ERP adherence ≤57.1% 67 1050 141 0.66 - 151 141 0.66 - Postoperative ERP adherence ≤75.0% 87 1054 0.001 0.95 83 74 0.50 - Postoperative ERP adherence ≤75.0% 87		No	475	2170	0.001	1.53	413	411	0.96	- 0.005
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Preoperative BT	Yes	17	36	0.01	0.07	13	10	0.67	- 0.03
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		No	471	2275	0.001	1.69	412	415	0.92	0.01
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Intraoperative and postoperative BT	Yes	14	86	0.001	0.20	12	11	1.00	- 0.01
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		No	474	2225	0.001	1.61	413	414	1.00	0.002
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Overall ERP adherence	≤75.0%	68	1222	0.001	1.12	67	67	1.00	0.00
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		>75.0%	420	1089	0.001	0.56	358	358	*/ * * 0.58 0.64 - 0.91 - 0.91 0.75 - 0.71 0.68 - 0.71 0.68 - 0.71 0.33 - 0.66 1.00 - 1.00 1.00 - 0.76 0.76 - 0.70 0.16 - 0.90 0.92 - 0.85 0.53 0.43 - 0.85 - 0.53 0.43 0.44 - 0.84 - - 0.70 - 1.00 1.00 - - 0.84 - - 0.92 - - 1.00 - - 0.64 - - 0.65 - - 0.65 - - 0.66 - - 0.65<	0.00
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Preoperative ERP adherence	≤57.1%	67	962	0.001	0.91	66	60	0.64	- 0.03
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		> 57.1%	421	1349	0.001	0.76	359	365	a 0.58 0.64 0.91 0.75 0.71 0.68 0.71 0.68 0.71 0.63 0.71 0.63 0.70 0.100 1.00 0.76 0.70 0.16 0.40 0.90 0.92 0.85 0.53 0.44 0.62 0.84 0.92 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.64 0.56 0.65 0.66 0.56 0.65 0.66 0.56 0.67 0.92 1.00 0.64 0.56 0.61 </td <td>0.01</td>	0.01
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Intraoperative ERP adherence	≤88.9%	320	1927	0.001	1.44	274	284	0.64	0.03
> 75.0% 401 1257 0.001 0.71 342 351 0.69 Overall morbidity Yes 106 625 0.001 0.57 89 99 0.49 No 382 1686 0.001 1.10 336 326 0.65 - Major morbidity Yes 19 172 0.001 0.30 15 28 0.06 No 469 2139 0.001 1.49 410 397 0.56 - Overall AL Yes 13 127 0.001 0.26 9 26 0.01 Major AL Yes 12 99 0.001 0.22 9 22 0.03 Major AL Yes 12 99 0.001 0.22 9 22 0.03 No 476 2212 0.001 1.58 416 403 0.56 - Overall AB Yes 4 98 0.001 0.		> 88.9%	168	384	0.001	0.26	151	141	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	- 0.03
Overall morbidity Yes 106 625 0.001 0.57 89 99 0.49 No 382 1686 0.001 1.10 336 326 0.65 - Major morbidity Yes 19 172 0.001 0.30 15 28 0.06 No 469 2139 0.001 1.49 410 397 0.56 - Overall AL Yes 13 127 0.001 0.26 9 26 0.01 - Major AL Yes 12 99 0.001 0.22 9 22 0.03 - Major AL Yes 12 99 0.001 0.22 9 22 0.03 - Overall AB Yes 4 98 0.001 0.25 4 8 0.38 -	Postoperative ERP adherence	≤75.0%	87	1054	0.001	0.95	83	74	0.50	- 0.04
No 382 1686 0.001 1.10 336 326 0.65 - Major morbidity Yes 19 172 0.001 0.30 15 28 0.06 - No 469 2139 0.001 1.49 410 397 0.56 - Overall AL Yes 13 127 0.001 0.26 9 26 0.01 - Major AL Yes 12 99 0.001 0.22 9 22 0.03 - Major AL Yes 12 99 0.001 0.22 9 22 0.03 - No 476 2212 0.001 1.58 416 403 0.56 - Overall AB Yes 4 98 0.001 0.25 4 8 0.38 No 484 2213 0.001 1.57 421 417 0.88 -		> 75.0%	401	1257	0.001	0.71	342	351	0.69	0.02
No 382 1686 0.001 1.10 336 326 0.65 - Major morbidity Yes 19 172 0.001 0.30 15 28 0.06 - No 469 2139 0.001 1.49 410 397 0.56 - Overall AL Yes 13 127 0.001 0.26 9 26 0.01 - Major AL Yes 12 99 0.001 0.22 9 22 0.03 - Major AL Yes 12 99 0.001 0.22 9 22 0.03 - No 476 2212 0.001 1.58 416 403 0.56 - Overall AB Yes 4 98 0.001 0.25 4 8 0.38 No 484 2213 0.001 1.57 421 417 0.88 -	Overall morbidity	Yes	106	625	0.001	0.57	89	99	0.49	0.04
Major morbidity Yes 19 172 0.001 0.30 15 28 0.06 No 469 2139 0.001 1.49 410 397 0.56 - Overall AL Yes 13 127 0.001 0.26 9 26 0.01 Major AL Yes 12 99 0.001 0.22 9 22 0.03 No 476 2212 0.001 1.58 416 403 0.56 - No 476 2212 0.001 1.58 416 403 0.56 - Overall AB Yes 4 98 0.001 0.25 4 8 0.38 No 484 2213 0.001 1.57 421 417 0.88 -	-		382						0.65	-0.02
No 469 2139 0.001 1.49 410 397 0.56 - Overall AL Yes 13 127 0.001 0.26 9 26 0.01 No 475 2184 0.001 1.55 416 399 0.44 - Major AL Yes 12 99 0.001 0.22 9 22 0.03 No 476 2212 0.001 1.58 416 403 0.56 - Overall AB Yes 4 98 0.001 0.25 4 8 0.38 No 484 2213 0.001 1.57 421 417 0.88 -	Major morbidity				0.001				0.06	0.10
Overall AL Yes 13 127 0.001 0.26 9 26 0.01 No 475 2184 0.001 1.55 416 399 0.44 - Major AL Yes 12 99 0.001 0.22 9 22 0.03 No 476 2212 0.001 1.58 416 403 0.56 - Overall AB Yes 4 98 0.001 0.25 4 8 0.38 No 484 2213 0.001 1.57 421 417 0.88 -		No						397	0.56	- 0.03
No 475 2184 0.001 1.55 416 399 0.44 - Major AL Yes 12 99 0.001 0.22 9 22 0.03 - No 476 2212 0.001 1.58 416 403 0.56 - Overall AB Yes 4 98 0.001 0.25 4 8 0.38 No 484 2213 0.001 1.57 421 417 0.88 -	Overall AL									0.14
Major AL Yes 12 99 0.01 0.22 9 22 0.03 No 476 2212 0.001 1.58 416 403 0.56 - Overall AB Yes 4 98 0.001 0.25 4 8 0.38 No 484 2213 0.001 1.57 421 417 0.88 -										
No 476 2212 0.001 1.58 416 403 0.56 - Overall AB Yes 4 98 0.001 0.25 4 8 0.38 No 484 2213 0.001 1.57 421 417 0.88 -	Major AL									0.11
Overall AB Yes 4 98 0.001 0.25 4 8 0.38 No 484 2213 0.001 1.57 421 417 0.88 -										- 0.03
No 484 2213 0.001 1.57 421 417 0.88 -	Overall AB									0.06
										- 0.01
	Mortality									0.02

^aStudent's test for proportions.

AB, anastomotic bleeding; AL, anastomotic leakage; ASA, American Society of Anesthesiologists; BT, blood transfusion(s); CS, circular stapler; ERP, enhanced recovery pathway; SMD, standardized mean difference.




Figure 2. (A) Jitter plot distribution of propensity scores in treatment and control groups. (B) Love plot of covariates' standardized mean differences between treatment and control groups before and after matching; the vertical lines represent the interval of ± 0.1 within which balance is considered acceptable. ERP, enhanced recovery pathway.

morbidity), corresponding to the need to treat 25 patients to avoid one AL (33 patients to avoid one major AL and/or one major adverse event). The finding that a CS diameter of at least 30 mm is linked to a significantly lower risk of overall and major morbidity deserves further investigation since the available evidence is controversial^[32,33].

The main strength of this study is its methodology: a large database gathered during two prospective multicenter studies was analyzed through a PSMA that perfectly responded to the EQUATOR (Enhancing the QUAlity and Transparency Of Health Research) network reporting guidelines^[22]. Although observational studies cannot be regarded as a replacement for randomized studies, data generated from large observational cohorts have been increasingly used to evaluate important clinical questions where data from randomized trials are limited or do not exist^[34], mainly because of the lower barriers and cost to subject recruitment. PSMA offers an alternative approach for estimating treatment effects with observational data when randomized trials are not feasible or unethical or when researchers need to assess treatment effects based on real-life data collected through the observation of systems as they operate in normal practice without any intervention implemented by randomized assignment rules, responding to the frequent need to draw conditioned casual inferences from quasi-experimental studies. To account for the conditional probability of treatment selection, thus reducing confounding bias, PSMA presents analytical and interpretation challenges that need to be addressed to maintain the reproducibility of its results, which in recent years has been recognized as a crucial element of high-quality research^[35].

The relevant quality of the PSMA used in the present study is based on: (1) a rigorous patients' selection from the parent population, performed upon explicit criteria: to limit data heterogeneity, several potential confounders^[36-39] related to the surgical procedure or to the anastomosis itself (any resection different from left colectomy and/or anterior resection, and any anastomosis different from end-to-end), as well as any variable exclusively impacting on subgroups of patients (anastomosis located <5 cm from external anal verge, neoadjuvant therapy, CS diameter 25 mm, proximal protective stoma) were excluded; (2) a reasoned inclusion of 20 conditioning variables (covariates): resections for both malignant and benign diseases in consideration that the stapled end-toend anastomosis is the same, despite different resection and vascular control criteria; center volume to account for the potential heterogeneity of multicenter, clustered data; adherence to the ERP to account for the potential heterogeneity of medical, anesthesiological, and surgical perioperative management and its impact on the measured outcomes^[2]; type of resection in relation to the heterogeneity of the treatment for malignant and benign diseases; intracorporeal or extracorporeal anastomosis, although no difference in the AL risk has recently been reported^[40]; CS diameter because its association with the AL risk is still unclear^[32,33]; (3) a clear, sheer and restrictive balance algorithm (Fig. 1), particularly regarding caliper = 0.1, matching ratio = 1:1, complete balance assessment, a covariate to number of patients per treatment arm ratio = 1:21; (4) complete description of software package and of its related analytic details; (5) evaluation of the treatment effect through an adjusted multiple regression model including the same 20 covariates used for matching; (6) accounting for unmeasured confounders by a sensitivity analysis.

Another strength of this study is the large number of enrolled patients in a well-defined time-lapse in a large number of centers,

Adjusted multiple regression analysis for primary endpoints.

		Overall AL		Major AL		Overall AB		
Variable	Pattern	OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	Р	
Circular stapler	Three-row	0.33 (0.15–0.73)	0.006	0.39 (0.17–0.87)	0.022	0.32 (0.08–1.23)	0.098	
	Two-row	Reference		Reference		Reference		
Age	< 65.2 years	Reference		Reference		Reference		
	\geq 65.2 years	0.95 (0.43-2.11)	0.91	0.89 (0.38-2.07)	0.79	1.31 (0.34-5.04)	0.69	
Sex	Male	0.91 (0.45-1.87)	0.81	0.71 (0.33-1.50)	0.37	3.93 (0.92-16.78)	0.06	
	Female	Reference		Reference		Reference		
ASA class	I–II	Reference		Reference		Reference		
	III	1.63 (0.73-3.63)	0.24	1.35 (0.56-3.24)	0.50	0.22 (0.03-1.40)	0.11	
Body mass index	\leq 25 kg/m ²	Reference		Reference		Reference		
	$> 25 \text{ kg/m}^2$	1.11 (0.54-2.29)	0.78	1.19 (0.55-2.58)	0.66	0.65 (0.19-2.18)	0.49	
Diabetes	Yes	1.28 (0.41-4.00)	0.68	1.36 (0.41-4.46)	0.62	1.23 (0.13–12.13)	0.86	
	No	Reference		Reference		Reference		
Chronic renal failure	Yes	Not estimable	_	Not estimable	_	Not estimable	_	
	No							
Chronic liver disease	Yes	Not estimable	_	Not estimable	_	Not estimable	_	
	No							
Surgery for malignancy	Yes	0.87 (0.39–1.95)	0.74	0.96 (0.42-2.20)	0.92	0.35 (0.09–1.45)	0.15	
ourgery for manghaney	No	Reference	0.74	Reference	0.02	Reference	0.10	
Type of resection	Anterior resection	Reference		Reference		Reference		
Type of resection	Left colectomy	1.18 (0.45–3.09)	0.74	1.60 (0.52-4.94)	0.42	1.29 (0.14–11.81)	0.82	
Diameter of CS	< 30 mm	Reference	0.74	Reference	0.42	Reference	0.02	
	< 30 mm	0.74 (0.36–1.52)	0.41	0.64 (0.30–1.38)	0.26	1.04 (0.28–3.82)	0.95	
Anastomosis	≥ 50 mm Intracorporeal	0.65 (0.12–3.56)	0.41	0.67 (0.11–3.91)	0.20	1.37 (0.03–73.55)	0.95	
Anastomosis		Reference	0.02	Reference	0.05	Reference	0.00	
Operation length	Extracorporeal < 180 min	Reference		Reference		Reference		
	—		0.10		0.17		0.24	
O	> 180 min	1.80 (0.86–3.75)	0.12	1.73 (0.80–3.74)	0.17	0.54 (0.15–1.91)	0.34	
Center volume	Low	Reference	0.00	Reference	0.00	Reference	0.45	
<u>_</u>	High	0.66 (0.28–1.54)	0.33	0.62 (0.25–1.53)	0.30	1.97 (0.34–11.54)	0.45	
Open surgery	Yes	Reference	0.00	Reference	0.47	Reference	0.00	
D	No	0.32 (0.04–2.33)	0.26	0.44 (0.05–4.05)	0.47	0.16 (0.00–9.34)	0.38	
Preoperative BT	Yes	0.82 (0.08-8.01)	0.86	2.95 (0.52–16.67)	0.22	9.60 (0.79–115.88)	0.08	
	No	Reference		Reference		Reference		
Intraoperative/postoperative BT	Yes					Ref		
	No	Not estimable	-	Not estimable	-	5.25 (0.40–68.71)	0.21	
Overall ERP adherence	≤75.0%	Reference		Reference		Reference		
	> 75.0%	1.25 (0.26-6.00)	0.78	2.26 (0.41-12.58)	0.35	11.7 (0.81–169.61)	0.07	
Preoperative ERP adherence	≤ 57.1%	Reference		Reference		Reference		
	> 57.1%	1.44 (0.42–4.97)	0.56	1.31 (0.35–4.91)	0.69	0.10 (0.02-0.48)	0.004	
Intraoperative ERP adherence	$\leq 88.9\%$	Reference		Reference		Reference		
	> 88.9%	1.18 (0.53–2.61)	0.56	1.31 (0.35–4.91)	0.69	0.60 (0.14-2.59)	0.49	
Postoperative ERP adherence	≤75.0%	Reference		Reference		Reference		
	> 75.0%	0.85 (0.23-3.08)	0.80	0.60 (0.17-2.20)	0.44	0.23 (0.03-1.62)	0.14	
Sensitivity analysis		Г		Г		Г		
		1.5	0.06	1.3	0.07	1.0	0.19	

AB, anastomotic bleeding; AL, anastomotic leakage; ASA, American Society of Anesthesiologists; BT, blood transfusion(s); CS, circular stapler; ERP, enhanced recovery pathway; OR (95% Cl), odds ratio and 95% confidence intervals.

representing a very wide sample of surgical units performing colorectal resections in Italy. Although the multicenter nature of the considered data may be a definite source of a clustering bias, it is undoubtedly representative of real-life data.

However, this study had several limitations, and the results should be interpreted with caution. First, several controversial risk factors for AL were not measured or recorded in the parent studies: disease stage^[41], single surgeon's experience^[42,43], level of vascular control^[44], splenic flexure mobilization^[45], rectal stump management^[46], intraoperative anastomotic testing, and reinforcement^[47]. The second limitation is represented by the impact of potential residual, known or unknown, confounding factors which are

intrinsic to observational studies. This impact seems to be not relevant in this study. Actually, according to the sensitivity analysis (Tables 5, 6), a potential model deviation from random assignment due to unknown and/or unmeasured confounders, which can alter the results, was estimated at 50% ($\Gamma = 1.5$) for overall AL risk, 30% ($\Gamma = 1.3$) for major AL risk, and 20% ($\Gamma = 1.2$) for major morbidity risk. On the other hand, lower values ($\Gamma = 1.0$) were recorded for overall morbidity (Table 6), indicating that unknown and/or unmeasured confounders may account for the controversial findings regarding CS diameter. Another limitation is the lack of testing for the same hypothesis by using the powered two-row CS as the treatment variable. A PSMA has not been performed because only

Adjusted multiple regression analysis for secondary endpoints.

Variable Pattern OR (95% C) P OR (95% C) P OR (95% C) Circular stapler Tme-row Reference Reference Reference Reference Age < 65.2 years Beforence Reference Reference Reference Sex Male 1.01 (0.72-1.42) 0.97 0.67 (0.35-1.23) 0.23 0.70 (0.14-3.51) ASA class H Reference Reference Reference Reference 600 mass index ≥ 25 kg/m² Reference Reference Reference ≥ 25 kg/m² Reference Reference Reference Reference			Overall morbi	dity	Major morbid	ity	Mortality	
Two row Reference Reference Reference Reference Reference Reference Age $< 65.2\ years$ 1.05 (0.73–1.53) 0.78 0.80 (0.38–1.66) 0.54 0.44 (0.07–2.80) Sax Male 1.01 (0.72–1.42) 0.97 0.67 (0.35–1.26) 0.23 0.70 (0.14–3.51) Sax Hal Reference Reference Reference Reference ASA class Hal Reference Reference Reference Reference Body mass index $\leq 25\ kg/m^2$ 1.04 (0.74–1.46) 0.82 0.81 (0.43–1.55) 0.53 1.07 (0.21–5.38) Diabetes Yes 0.87 (0.48–1.56) 0.63 1.36 (0.51–3.60) 0.54 Not estimable Chronic renal failure Yes 0.47 (0.42–7.68) 0.43 Not estimable Not estimable Chronic Iveral failure Yes 1.02 (0.70–1.49) 0.92 2.05 (0.95–4.41) 0.07 2.80 (0.47–16.53) Surgery for malignancy Yes 1.26 (0.54–1.48) 0.43 1.30 (0.54–3.15) 0.56 Not estim	Variable	Pattern	OR (95% CI)	Р	OR (95% CI)	Р	OR (95% CI)	Р
Age ≤ 65.2 years Reference Reference Reference Reference Sox Male 1.01 (0.72-1.42) 0.97 0.67 (0.35-1.28) 0.23 0.70 (0.14-3.51) SA class HI Reference Reference Reference Reference SA class HI 1.02 (0.68-1.52) 0.33 1.45 (0.68-3.03) 0.33 1.25 (0.17-9.18) Body mass index ≤ 25 kg/m² 1.04 (0.74-1.46) 0.82 0.81 (0.43-1.55) 0.53 1.07 (0.21-5.38) Diabetes Yes 0.67 (0.48-1.56) 0.63 1.66 (0.07-5.01) 0.64 Chronic ineral failure Yes Reference Reference Reference Reference Sugery for matignancy Yes 1.80 (0.42-7.68) 0.43 Not estimable - Not estimable Sugery for matignancy Yes 1.20 (0.70-1.49) 0.92 2.05 (0.95-4.11) 0.07 2.80 (0.47-16.53) Dianeter of CS < 30 mm	Circular stapler	Three-row	0.87 (0.63–1.21)	0.42	0.47 (0.24-0.91)	0.026	0.97 (0.20-4.72)	0.97
2 = 65.2 pears 1.05 (0.73-1.53) 0.78 0.80 (0.38-1.66) 0.54 0.44 (0.77-2.80) Sex Male 1.01 (0.72-1.42) 0.97 0.67 (0.55-1.26) 0.23 0.70 (0.14-3.51) Female Reference Reference Reference Reference Reference 2525 kg/m ² Reference Reference Reference 2525 kg/m ² Reference Reference Reference Reference 2525 kg/m ² 1.04 (0.74-1.46) 0.82 0.81 (0.43-1.55) 0.53 1.07 (0.21-5.38) Diabetes Yes 0.87 (0.48-1.56) 0.63 1.36 (0.51-3.60) 0.54 Not estimable No Reference Reference No Sector Not estimable No Reference Reference Reference Not estimable No Reference Reference Reference Reference No Sector Not estimable No Reference Reference Reference Reference No Sector Not estimable No Reference Reference Reference Reference Reference No Reference Reference Reference Reference No Reference Reference Reference Reference Reference Not estimable No Reference Reference Reference Reference Reference No Reference Reference Reference Reference No Reference Reference Reference Reference No Reference Reference Reference Reference Reference Reference Reference Reference Sector No Reference Reference Reference Reference Reference Sector 2.30 mm 0.66 (0.47-0.92) 0.02 0.33 (0.54-3.15) 0.56 Not estimable Etracorporeal 1.23 (0.44-3.43) 0.59 (0.561-1.43) 0.51 (0.561-3.21) 0.46 Not estimable No Statistical Proces Reference Reference Reference Reference Reference Reference Sector Sector No Reference Reference Reference Reference No 0.56 (0.17-1.64) 0.33 (0.56-3.21) 0.14 (2.68 (0.47-15.24) 0.57 (0.56-3.21) 0.14 (2.68 (0.47-15.24) 0.57 (0.56-3.21) 0.14 (2.68 (0.47-15.24) 0.59 (0.57-15.24) 0.59 (0.57-15.26) 0.59 (0.57-15.26) 0.59 (0.57 (0.56 (0.56) 0.502 0.57 (0.56 (0.56) 0.502 0.57 (0.56 (0.56) 0.502 0.57 (0.56 (0.56) 0.57 (0.56 (0.56) 0.57 (0.56 (0.56) 0.57 (0.56 (0.56) 0.57 (0.56 (0.56) 0.57 (0.56 (0.56) 0.57 (0.56 (0.56) 0.57 (0.56 (0.56) 0.57 (0.56 (0.56) 0.57 (0.56 (0.56) 0.57 (0.56 (0.56) 0.57 (0.56 (0.56)		Two-row	Reference		Reference		Reference	
Sex Male 1.01 (0.72-142) 0.97 0.67 (0.57-128) 0.23 0.70 (0.14-3.51) ASA class I-II Reference Reference Reference Reference ASA class I-II Reference Reference Reference Reference Boly mass index $\leq 25 kg/m^2$ 1.04 (0.74-1.46) 0.82 0.81 (0.43-1.55) 0.53 1.07 (0.21-5.38) Diabates Yes 0.87 (0.65-3.77) 0.52 0.64 Not estimable Chronic renal failure Yes Reference Reference Reference Not estimable Chronic iver disease Yes 1.80 (0.42-7.68) 0.43 Not estimable - Not estimable Surgery for malignancy Yes 1.20 (0.70-1.49) 0.92 2.05 (0.95-4.41) 0.07 2.80 (0.47-16.53) Diameter of CS <30 mm	Age	< 65.2 years	Reference		Reference		Reference	
ASA classFernaleReferenceReferenceReferenceReferenceASA classI-IIReferenceReferenceReferenceBody mass index $\leq 25 kg/m^2$ 0.0 (0.84-1.52)0.931.45 (0.68-3.03)0.331.25 (0.17-9.18)Body mass index $\leq 25 kg/m^2$ ReferenceReferenceReferenceReference $\geq 25 kg/m^2$ 0.40 (7.4-1.65)0.631.36 (0.51-3.60)0.54Not estimableDiabetesYes0.87 (0.48-1.56)0.631.36 (0.57-3.60)0.54Not estimableChronic renal failureYesReferenceReferenceReferenceNo1.57 (0.65-3.77)0.320.60 (0.07-5.01)0.64Chronic iver diseaseYes1.00 (0.42-7.68)0.43Not estimable-Surgery for malignancyYes1.02 (0.70-1.49)0.922.05 (0.95-4.41)0.072.80 (0.47-16.53)Diameter of CS<30 mm		\geq 65.2 years	1.05 (0.73-1.53)	0.78	0.80 (0.38-1.66)	0.54	0.44 (0.07-2.80)	0.39
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Sex	Male	1.01 (0.72-1.42)	0.97	0.67 (0.35-1.28)	0.23	0.70 (0.14-3.51)	0.67
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Female	Reference		Reference		Reference	
Body mass index ≤ 25 kg/m² Peterence Reference Not Reference Not Reference Not Reference Not Reference Not Reference Not Reference Reference Not Reference R	ASA class	I–II	Reference		Reference		Reference	
$ \begin{tabular}{ c c c c c c c } \hline $25 kg/m^2 & 1.04 (0.74-1.46) & 0.82 & 0.81 (0.43-1.55) & 0.53 & 1.07 (0.21-5.38) \\ \hline $25 kg/m^2 & 0.87 (0.48-1.56) & 0.53 & 1.36 (0.51-3.66) & 0.54 & Not estimable \\ \hline $No & Reference & Reference & Reference & Not estimable \\ \hline $No & 1.57 (0.65-3.77) & 0.32 & 0.60 (0.75-0.11) & 0.64 & Not estimable \\ \hline $No & Reference & Reference & Not estimable & - & Not estimable \\ \hline $No & Reference & Reference$		III	1.02 (0.68-1.52)	0.93	1.45 (0.68-3.03)	0.33	1.25 (0.17–9.18)	0.82
Diabetes Yes 0.87 (0.48–1.56) 0.63 1.36 (0.51–3.60) 0.54 Not estimable No Reference Reference Reference Not estimable Chronic renal failure Yes Reference Reference Not estimable Chronic liver disease Yes 1.80 (0.42–7.68) 0.43 Not estimable – Not estimable Surgery for malignancy Yes 1.02 (0.70–1.49) 0.92 2.05 (0.95–4.41) 0.07 2.80 (0.47–16.53) Prop of resection Reference Reference Reference Reference Jianeter of CS < 30 mm	Body mass index	\leq 25 kg/m ²	Reference		Reference		Reference	
Diabetes Yes 0.87 (0.48–1.56) 0.63 1.36 (0.51–3.60) 0.54 Not estimable No Reference Reference Reference Not estimable Chronic renal failure Yes Reference Reference Not estimable No 1.57 (0.65–3.77) 0.32 0.60 (0.07–5.01) 0.64 Chronic liver disease Yes 1.80 (0.42–7.68) 0.43 Not estimable – Not estimable Surgery for malignancy Yes 1.02 (0.70–1.49) 0.92 2.05 (0.95–4.41) 0.07 2.80 (0.47–16.53) Type of resection Anterior resection Reference Reference Reference Type of resection Anterior resection Reference Reference Reference Diameter of CS < 30 mm	-	$> 25 \text{ kg/m}^2$	1.04 (0.74-1.46)	0.82	0.81 (0.43-1.55)	0.53	1.07 (0.21-5.38)	0.93
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Diabetes	•	0.87 (0.48-1.56)		1.36 (0.51-3.60)		Not estimable	_
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		No	```		()			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Chronic renal failure	Yes	Reference		Reference		Not estimable	_
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		No	1.57 (0.65-3.77)	0.32	0.60 (0.07-5.01)	0.64		
$\begin{tabular}{ c c c c c } \hline $$ No & $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$	Chronic liver disease	Yes	```		()		Not estimable	_
NoReferenceReferenceReferenceType of resectionAnterior resectionReferenceReferenceDiameter of CS< 30 mm			· · · ·					
NoReferenceReferenceReferenceType of resectionAnterior resectionReferenceReferenceDiameter of CS< 30 mm	Surgery for malignancy	Yes	1.02 (0.70-1.49)	0.92	2.05 (0.95-4.41)	0.07	2.80 (0.47-16.53)	0.26
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		No	(/		(/		()	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Type of resection	Anterior resection	Reference		Reference			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				0.83		0.56	Not estimable	_
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Diameter of CS	,			· · · · ·			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				0.02		0.002		0.23
$\begin{tabular}{ c c c c c c } \hline Extracorporeal Reference ST5.0% Reference Reference Reference Reference Reference ST5.1% Reference Reference Reference Reference Reference Reference ST.1% Reference Reference Reference Reference Reference ST.1% Reference Reference Reference Reference Reference ST.1% Reference Reference Reference Reference Reference Reference Reference Reference ST.1% Reference Reference Reference Reference Reference ST.1% Reference Reference Reference Reference Reference ST.1% Reference Reference Reference Reference ST.1% Reference Reference Reference Reference ST.1% Reference Reference Reference Reference Reference ST.1% Reference Reference Reference Reference ST.1% Reference Reference Reference Reference ST.1% Reference Reference Reference Reference R$	Anastomosis	_ • •	· · · · ·		· · · · ·		· · · · ·	-
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		1	```		()			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Operation length						Reference	
$\begin{array}{c cccc} \mbox{Center volume} & \mbox{Low} & \mbox{Reference} & \mb$		—		0.36		0.14		0.27
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Center volume		· · · · ·	0.00		0111		0.2.
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				0.35		0.91		0.91
No 0.56 (0.17–1.84) 0.34 Not estimable - Not estimable Preoperative BT Yes 0.73 (0.24–2.29) 0.59 1.04 (0.13–8.63) 0.97 Not estimable Intraoperative/postoperative BT Yes 1.34 (0.50–3.60) 0.57 Not estimable - Not estimable Overall ERP adherence ≤ 75.0% Reference Reference Reference Reference Overall ERP adherence ≤ 75.0% Reference Reference Reference Reference Preoperative ERP adherence ≤ 57.1% Reference Reference Reference 57.1% 0.72 (0.41–1.25) 0.24 0.74 (0.28–1.93) 0.54 1.29 (0.13–12.45) Intraoperative ERP adherence ≤ 88.9% Reference Reference Reference 88.9% 1.05 (0.73–1.52) 0.80 1.93 (0.93–3.98) 0.08 2.04 (0.24–17.03) Postoperative ERP adherence ≤ 75.0% Reference Reference Reference > 75.0% 1.17 (0.62–2.20) 0.64 0.44 (0.15–1.30) 0.14	Open surgery	0	```	0.00	1100 (0111 2110)	0101		0101
Preoperative BT Yes 0.73 (0.24–2.29) 0.59 1.04 (0.13–8.63) 0.97 Not estimable Intraoperative/postoperative BT Yes 1.34 (0.50–3.60) 0.57 Not estimable – Not estimable Overall ERP adherence $\leq 75.0\%$ Reference Reference Reference Reference Overall ERP adherence $\leq 75.0\%$ Reference Reference Reference Reference Preoperative ERP adherence $\leq 57.1\%$ Reference Reference Reference Reference $> 57.1\%$ 0.72 (0.41–1.25) 0.24 0.74 (0.28–1.93) 0.54 1.29 (0.13–12.45) Intraoperative ERP adherence $\leq 88.9\%$ Reference Reference Reference $> 88.9\%$ 1.05 (0.73–1.52) 0.80 1.93 (0.93–3.98) 0.08 2.04 (0.24–17.03) Postoperative ERP adherence $\leq 75.0\%$ Reference Reference Reference $> 88.9\%$ 1.05 (0.73–1.52) 0.80 1.93 (0.93–3.98) 0.08 2.04 (0.24–17.03) Postoperative ERP adherence $\leq 75.0\%$ <td< td=""><td>opon ourgory</td><td></td><td></td><td>0.34</td><td>Not estimable</td><td>_</td><td>Not estimable</td><td>_</td></td<>	opon ourgory			0.34	Not estimable	_	Not estimable	_
No Reference Reference Intraoperative/postoperative BT Yes 1.34 (0.50–3.60) 0.57 Not estimable – Not estimable Overall ERP adherence $\leq 75.0\%$ Reference Reference Reference Reference Overall ERP adherence $\leq 75.0\%$ Reference Reference Reference Reference $>75.0\%$ 1.59 (0.74–3.43) 0.24 1.41 (0.37–5.42) 0.62 0.94 (0.06–15.95) Preoperative ERP adherence $\leq 57.1\%$ Reference Reference Reference $>57.1\%$ 0.72 (0.41–1.25) 0.24 0.74 (0.28–1.93) 0.54 1.29 (0.13–12.45) Intraoperative ERP adherence $\leq 88.9\%$ Reference Reference Reference $> 88.9\%$ 1.05 (0.73–1.52) 0.80 1.93 (0.93–3.98) 0.08 2.04 (0.24–17.03) Postoperative ERP adherence $\leq 75.0\%$ Reference Reference Reference $> 75.0\%$ 1.17 (0.62–2.20) 0.64 0.44 (0.15–1.30) 0.14 0.09 (0.09–1.03) Sensitivity analysis	Preoperative BT		```			0.97		_
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			```	0.00	()	0.01		
$\begin{tabular}{ c c c c c c c } \hline N_0 & Reference &$	Intraoperative/postoperative BT			0.57		_	Not estimable	_
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				0.07				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Overall ERP adherence				Reference		Reference	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		—		0 24		0.62		0.97
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Preoperative ERP adherence		(/	0.2-1	· · · · ·	0.02	(0.07
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		_		0 24		0 54		0.82
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Intraoperative EBP adherence		· · · ·	0.2-1	(/	0.04	. ,	0.02
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				0.80		0.08		0.51
- -	Postoperative FBP adherence		· · · · ·	0.00	· · · ·	0.00		0.01
Sensitivity analysis Γ Γ Γ				0.64		0 14		0.05
	Sensitivity analysis	× 10.070		0.04	()	0.17	()	0.00
			1	0.23	1 1.2	0.09	1	0.50
I U.2.5 I.2 U.09 I			I	0.20	1.2	0.03	1	0.00

ASA, American Society of Anesthesiologists; BT, blood transfusion(s); CS, circular stapler; ERP, enhanced recovery pathway; OR (95% CI), odds ratio and 95% confidence intervals.

172 cases treated with the powered two-row CS were available in the examined population (Table 1), and this small number of cases would not have allowed the use of the same PSMA algorithm used for the three-row CS. Moreover, two previous PSMAs were performed on the same topic: the first^[48] using the powered two-row CS and the second^[16] using the three-row CS in the treatment arm. According to PSMA reporting guidelines^[22], both were deeply biased regarding a limited number of cases, retrospective data, matching ratio = 1:2, caliper = 0.2, the inclusion of a limited (8–11) number of covariates, and an incomplete description of the matching algorithm. As a consequence, the 10% AL absolute risk reduction using these devices recorded by both studies appears at least unrealistic, considering that any stapling device is not a 'magic bullet' and that there is always a human being firing it^[9].

Finally, although data quality control was performed and repeated at various levels, potential measurement errors by the participating investigators could not be ruled out.

Conclusions

This study clearly highlighted that technological change in stapling devices might play a definite role in limiting the risk of anastomotic leakage and its related morbidity.

Ethical approval

Both studies were conducted in accordance with the Declaration of Helsinki and the guidelines for good clinical practice E6 (R2). The study protocols were approved by the ethics committee of the coordinating center (Marche Regional Ethics Committee – CERM – 2018/334 released on 28 November 2018 for iCral2; CERM – 2020/192 released on 30 July 2020 for iCral3) and registered at ClinicalTrials.gov (NCT03771456 for iCral2 and NCT04397627 for iCral3).

Sources of funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Medtronic SI-Italy provided unconditioned support to the organization of three iCral2 study investigator meetings, held in Rome, Italy – October 2018, Matera, Italy – June 2019, and Bologna, Italy – October 2019.

Author contributions

M.C., S.G., G.R., M.G.V., F.B., G.B., and M.S.: concept and design; M.C., S.G., F.M., G.R., M.G.V., F.B, G.B., and M.S.: acquisition, analysis, or interpretation of data; M.C., S.G., and F. M.: drafting of the manuscript; M.C., S.G., F.M., G.R., M.G.V., F.B., G.B., and M.S.: critical revision of the manuscript for important intellectual content; F.M. and S.G.: statistical analysis.

Conflicts of interest disclosure

Dr Catarci reports personal fees from Baxter Spa outside the submitted work. Dr Guadagni, Masedu, Ruffo, Viola, Borghi, Baldazzi, and Scatizzi have no competing interests.

Research registration unique identifying number (UIN)

None.

Guarantor

Marco Catarci, iCral Study Group coordinator, had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis.

Data availability statement

Individual participant-level anonymized datasets were made available for both parent studies and presented analysis upon reasonable request by contacting the study coordinator.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Presentation

None.

Assistance with the study: iCral study group co-investigators are: Felice Pirozzi¹², MD, Paolo Delrio¹³, MD, Gianluca Garulli¹⁴, MD, Pierluigi Marini¹⁵, MD, Roberto Campagnacci¹⁶, MD, Raffaele De Luca¹⁷, MD, Ferdinando Ficari¹⁸, MD, Giuseppe Sica¹⁹, MD, Stefano Scabini²⁰, MD, Andrea Liverani²¹, MD, Marco Caricato²², MD, FACS, Alberto Patriti²³, MD, Stefano Mancini²⁴, MD, Gian Luca Baiocchi²⁵, MD, FACS, Roberto Santoro²⁶, MD, Walter Siquini²⁷, MD, Gianluca Guercioni², MD, Massimo Basti²⁸, MD, Corrado Pedrazzani²⁹, MD, Mauro Totis³⁰, MD, Alessandro Carrara³¹, MD, Andrea Lucchi³², MD, FACS, Maurizio Pavanello³³, MD, Andrea Muratore³⁴, MD, Stefano D'Ugo³⁵, MD, Alberto Di Leo³⁶, MD, Giusto Pignata³⁷, MD, Ugo Elmore³⁸, MD, Gabriele Anania³⁹, MD, Massimo Carlini⁴⁰, MD, FACS, Francesco Corcione⁴¹, MD, Nereo Vettoretto⁴², MD, Graziano Longo⁴³, MD, Mario Sorrentino⁴⁴, MD, Antonio Giuliani⁴⁵, MD, Giovanni Ferrari⁴⁶, MD, Lucio Taglietti⁴⁷, MD, Augusto Verzelli⁴⁸, MD, Mariantonietta Di Cosmo⁴⁹, MD, Davide Cavaliere⁵⁰, MD, Marco Milone⁵¹, MD, Stefano Rausei⁵², MD, Giovanni Ciaccio⁵³, MD, Giovanni Tebala⁵⁴, MD, FACS, FRCS, Giuseppe Brisinda⁵⁵, MD, Stefano Berti⁵⁶, MD, Paolo Millo⁵⁷, MD, Luigi Boni⁵⁸, MD, FACS, Mario Guerrieri⁵⁹, MD, Roberto Persiani⁶⁰, MD, Dario Parini⁶¹, MD, Antonino Spinelli⁶², MD, Michele Genna⁶³, MD, Vincenzo Bottino⁶⁴, MD, Andrea Coratti⁶⁵, MD, Dario Scala⁶⁶, MD, Umberto Rivolta⁶⁷, MD, Micaela Piccoli⁶⁸, MD, FACS, Carlo Talarico⁶⁹, MD, Franco Roviello⁷⁰, MD, Alessandro Anastasi⁷¹, MD, Giuseppe Maria Ettorre⁷², MD, Mauro Montuori⁷³, MD, Pierpaolo Mariani⁷⁴, MD, Nicolò de Manzini⁷⁵, MD, Annibale Donini⁷⁶, MD, Mariano Fortunato Armellino⁷⁷, MD, Carlo Feo⁷⁸, MD, Silvio Guerriero⁷⁹, MD, Andrea Costanzi⁸⁰, MD, Federico Marchesi⁸¹, MD, Moreno Cicetti⁸², MD, Paolo Ciano¹, MD, Michele Benedetti¹, MD, Leonardo Antonio Montemurro¹, MD, Maria Sole Mattei¹, MD, Elena Belloni¹, MD, Daniela Apa¹, MD, Matteo Di Carlo¹, MD, Marco Clementi³, MD, Elisa Bertocchi⁵, MD, Gaia Masini⁵, MD, Amedeo Altamura⁶, MD, Francesco Rubichi⁶, MD, Desirée Cianflocca⁸, MD, Marco Migliore⁸, MD, Diletta Cassini^{9,10}, MD, Lorenzo Pandolfini¹¹, MD, Alessandro Falsetto¹¹, MD, Antonio Sciuto¹², MD, Ugo Pace¹³, MD, Andrea Fares Bucci¹³, MD, Francesco Monari¹⁴, MD, Grazia Maria Attinà¹⁵, MD, Angela Maurizi¹⁶, MD, Michele Simone¹⁷, MD, Francesco Giudici¹⁸, MD, Fabio Cianchi¹⁸, MD, Gabriele Baldini¹⁸, MD, Bruno Sensi¹⁹, MD, Alessandra Aprile²⁰, MD, Domenico Soriero²⁰, MD, Andrea Scarinci²¹, MD, Gabriella Teresa Capolupo²², MD, FACS, Valerio Sisti²³, MD, Marcella Lodovica Ricci²³, MD, Andrea Sagnotta²⁴, MD, PhD, Sarah Molfino²⁵, MD, Pietro Amodio²⁶, MD, Alessandro Cardinali²⁷, MD, Simone Cicconi², MD, Irene Marziali², MD, Diletta Frazzini²⁸, MD, Cristian Conti²⁹, MD, Nicolò Tamini³⁰, MD, Marco Braga³⁰, MD, Michele Motter³¹, MD, Giuseppe Tirone³¹, MD, Giacomo Martorelli³², MD, Alban Cacurri³², MD, Carlo Di Marco³³, MD, Patrizia Marsanic³⁴, MD, Nicoletta Sveva Pipitone Federico³⁴, MD, Marcello Spampinato³⁵, MD, PhD, FEBS (HPB), Lorenzo Crepaz³⁶, MD, Jacopo Andreuccetti³⁷, MD, Ilaria Canfora³⁷, MD, Giulia Maggi³⁸, MD, Matteo Chiozza³⁹, MD, Domenico Spoletini⁴⁰, MD, Rosa Marcellinaro⁴⁰, MD, Giorgio Lisi⁴⁰, MD, Umberto Bracale⁴¹, MD, Roberto Peltrini⁴¹, MD, Maria Michela Di Nuzzo⁴¹, MD, Emanuele Botteri⁴², MD, Simone Santoni⁴³, MD, Massimo Stefanoni⁴⁴, MD, Giovanni Del Vecchio⁴⁵, MD,

Carmelo Magistro⁴⁶, MD, Silvia Ruggiero⁴⁷, MD, Arianna Birindelli⁴⁷, MD, Andrea Budassi⁴⁸, MD, Daniele Zigiotto⁴⁹, MD, Leonardo Solaini⁵⁰, MD, Giorgio Ercolani⁵⁰, MD, Giovanni Domenico De Palma⁵¹, MD, Silvia Tenconi⁵², MD, Paolo Locurto⁵³, MD, Antonio Di Cintio⁵⁴, MD, Maria Michela Chiarello⁵⁵, MD, Maria Cariati⁵⁵, MD, Andrea Gennai⁵⁶, MD, Manuela Grivon⁵⁷, MD, Elisa Cassinotti⁵⁸, MD, Monica Ortenzi⁵⁹, MD, Alberto Biondi⁶⁰, MD, Maurizio De Luca⁶¹, MD, Francesco Carrano⁶², MD, Francesca Fior⁶³, MD, Antonio Ferronetti⁶⁴, MD, Giuseppe Giuliani⁶⁵, MD, Graziella Marino⁶⁶, MD, Camillo Leonardo Bertoglio⁶⁷, MD, Francesca Pecchini⁶⁸, MD, Vincenzo Greco⁶⁹, MD, Roberto Piagnerelli⁷⁰, MD, Giuseppe Canonico⁷¹, MD, Marco Colasanti⁷², MD, Enrico Pinotti⁷³, MD, Roberta Carminati⁷⁴, MD, Edoardo Osenda⁷⁵, MD, Luigina Graziosi⁷⁶, MD, Ciro De Martino⁷⁷, MD, Giovanna Ioia⁷⁷, MD, Fioralba Pindozzi⁷⁸, MD, Lorenzo Organetti⁷⁹, MD, Gabriele La Gioia⁸², MD.

From the ¹²General Surgery Unit, ASL Napoli 2 Nord, Pozzuoli (NA); ¹³Colorectal Surgical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Giovanni Pascale IRCCS-Italia", Napoli; ¹⁴General Surgery Unit, Infermi Hospital, Rimini; ¹⁵General & Emergency Surgery Unit, San Camillo-Forlanini Hospital, Roma; ¹⁶General Surgery Unit, "C. Urbani" Hospital, Jesi (AN); ¹⁷Department of Surgical Oncology, IRCCS Istituto Tumori "Giovanni Paolo II", Bari; ¹⁸General Surgery and IBD Unit, Careggi University Hospital, Firenze; ¹⁹Minimally Invasive Surgery Unit, Policlinico Tor Vergata University Hospital, Roma; ²⁰General & Oncologic Surgery Unit, IRCCS "San Martino" National Cancer Center, Genova; ²¹General Surgery Unit, Regina Apostolorum Hospital, Albano Laziale (RM); ²²Colorectal Surgery Unit, Policlinico Campus BioMedico, Roma; ²³Department of Surgery, Marche Nord Hospital, Pesaro e Fano (PU); ²⁴General & Oncologic Surgery Unit, San Filippo Neri Hospital, ASL Roma 1;²⁵General Surgery Unit 3, Department of Clinical and Experimental Sciences, University of Brescia; ²⁶General Oncologic Surgery Unit, Belcolle Hospital, Viterbo; ²⁷General Surgery Unit, S. Lucia Hospital, Macerata; ²⁸General Surgery Unit, Spirito Santo Hospital, Pescara; ²⁹General & HPB Surgery Unit, University Hospital, Verona; ³⁰Colorectal Surgery Unit, San Gerardo Hospital, Verona; "Colorectal Surgery Unit, San Gerardo Hospital, ASST Monza; ³¹1st General Surgery Unit, S. Chiara Hospital, Trento; ³²General Surgery Unit, "Ceccarini" Hospital, Riccione (RN); ³³General Surgery Unit, AULSS2 Marca Trevigiana, Conegliano Veneto (TV); ³⁴General Surgery Unit, "E. Agnelli" Hospital, Pinerolo (TO); ³⁵General Surgery Unit, "V. Fazzi" Hospital, Lecce; ³⁶General and Minimally Invasive Surgery Unit, San Camillo Hospital, Trento; 372nd General Surgery Unit 2, Spedali Civili di Brescia; ³⁸Gastroenterologic Surgery Unit, IRCCS S. Raffaele Hospital, Milano; ³⁹General & Laparoscopic Surgery Unit, University Hospital, Ferrara; ⁴⁰General Surgery Unit, S. Eugenio Hospital, ASL Roma 2; ⁴¹General Oncologic and Mininvasive Surgery Unit, "Federico II" University, Napoli; ⁴²General Surgery Unit, Spedali Civili of Brescia, Montichiari (BS); ⁴³General Surgery Unit, Policlinico Casilino, Roma; ⁴⁴General Surgery Unit, Latisana-Palmanova Hospital, Friuli Centrale University (UD); ⁴⁵General Surgery Unit, S. Carlo Hospital, Potenza; ⁴⁶General Oncologic and Mininvasive Surgery Unit, Great Metropolitan Niguarda Hospital, Milano; ⁴⁷General Surgery Unit, ASST Valcamonica, Esine (BS); ⁴⁸General Surgery Unit, Profili Hospital, Fabriano

(AN); ⁴⁹General & Upper GI Surgery Unit, University Hospital, Verona; ⁵⁰General & Oncologic Surgery Unit, AUSL Romagna, Forlì (FC); ⁵¹General & Endoscopic Surgery Unit, "Federico II" University, Napoli; 52General Surgery Unit, Gallarate Hospital (VA); ⁵³General Surgery Unit, S. Elia Hospital, Caltanissetta; ⁵⁴General Surgery Unit, S. Maria Hospital, Terni; ⁵⁵General Surgery Unit, San Giovanni di Dio Hospital, Crotone; ⁵⁶General Surgery Unit, ASL 5 Liguria POLL, La Spezia; ⁵⁷General Surgery Unit, "U. Parini" Regional Hospital, Aosta; ⁵⁸General Surgery Unit, Fondazione IRCCS Ca' Granda, Policlinico Maggiore Hospital, Milano; 59 Surgical Clinic, Torrette Hospital, University of Ancona; ⁶⁰General Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma; ⁶¹General Surgery Unit, S. Maria della Misericordia Hospital, Rovigo; ⁶²Colorectal Surgery Unit, Humanitas University, Rozzano (MI); ⁶³General & Bariatric Surgery Unit, University Hospital, Verona; ⁶⁴General & Oncologic Surgery Unit, Evangelico Betania Hospital, Napoli; ⁶⁵General Surgery Unit, Misericordia Hospital, Grosseto; ⁶⁶Abdominal Oncologic Surgery Unit, Basilicata Oncologic Hospital, Rionero in Vulture (PZ); ⁶⁷General Surgery Unit, Fornaroli Hospital, ASST Ovest Milanese, Magenta (MI): ⁶⁸General Surgery Unit, Civil Hospital, Baggiovara (MO); ⁶⁹General Surgery Unit, Villa dei Gerani Hospital, Vibo Valentia (VV); ⁷⁰Surgical Clinic, University of Siena; ⁷¹General Surgery Unit, San Giovanni di Dio Hospital, Firenze; 72General & Transplant Surgery Unit, San Camillo-Forlanini Hospital, Roma; ⁷³General & Mininvasive Surgery Unit, S. Pietro Hospital, Ponte San Pietro (BG); ⁷⁴General Surgery Unit, Pesenti Fenaroli Hospital, Alzano Lombardo (BG); ⁷⁵Surgical Clinic, University of Trieste; ⁷⁶General & Emergency Surgery Unit, University of Perugia; ⁷⁷General & Emergency Surgery Unit, S. Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno; ⁷⁸General Surgery Unit, Delta Hospital, Lagosanto (FE); ⁷⁹General Surgery Unit, "F. Murri" Hospital, Fermo; ⁸⁰General Surgery Unit, S. Leopoldo Hospital, Merate (LC); ⁸¹Surgical Clinic, University of Parma; ⁸²General Surgery Unit, S. Maria della Misericordia Hospital, Urbino (PU); Italy.

References

- Mlambo B, Shih IF, Li Y, *et al.* The impact of operative approach on postoperative outcomes and healthcare utilization after colectomy. Surgery 2022;171:320–7.
- [2] Ripollés-Melchor J, Ramírez-Rodríguez JM, Casans-Francés R, et al. Association between use of enhanced recovery after surgery protocol and postoperative complications in colorectal surgery: the Postoperative Outcomes Within Enhanced Recovery After Surgery Protocol (POWER) Study. JAMA Surg 2019;154:725–36.
- [3] Boccola MA, Buettner PG, Rozen WM, et al. Risk factors and outcomes for anastomotic leakage in colorectal surgery: a single-institution analysis of 1576 patients. World J Surg 2011;35:186–95.
- [4] La Regina D, Di Giuseppe M, Lucchelli M, et al. Financial impact of anastomotic leakage in colorectal surgery. J Gastrointest Surg 2019;23: 580–6.
- [5] Bashir Mohamed K, Hansen CH, Krarup P-M, et al. The impact of anastomotic leakage on recurrence and long-term survival in patients with colonic cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2020;46:439–47.
- [6] Ravitch MM, Steichen FM. A stapling instrument for end-to-end inverting anastomosis in the gastrointestinal tract. Ann Surg 1979;189: 791–7.
- [7] Italian ColoRectal Anastomotic Leakage (iCral) study group. Colorectal surgery in Italy: a snapshot from the iCral study group. Updates Surg 2019;71:339–47.

a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IIQrHD3i3D0OdRyi7TvSFI4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 12/26/2024

- [8] Griffen FD, Knight CD Sr, Whitaker JM. The double stapling technique for low anterior resection. Results, modifications, and observations. Ann Surg 1990;211:745–51.
- [9] Slieker JC, Daams F, Mulder IM, *et al.* Systematic review of the technique of colorectal anastomosis. JAMA Surg 2013;148:190–201.
- [10] Sparreboom CL, van Groningen JT, Lingsma HF, et al. Different risk factors for early and late colorectal anastomotic leakage in a nationwide audit. Dis Colon Rectum 2018;61:1258–66.
- [11] Chung RS. Blood flow in colonic anastomoses. Effect of stapling and suturing. Ann Surg 1987;206:335–9.
- [12] Herzig DO, Ogilvie JW, Chudzinski A, et al. Assessment of a circular powered stapler for creation of anastomosis in left-sided colorectal surgery: a prospective cohort study. Int J Surg 2020;84:140–6.
- [13] Eschbach M, Sindberg GM, Godek ML, et al. Micro-CT imaging as a method for comparing perfusion in graduated-height and single-height surgical staple lines. Med Devices (Auckl) 2018;11:267–73.
- [14] Nakanishi R, Fujimoto Y, Sugiyama M, et al. Clinical impact of the triplelayered circular stapler for reducing the anastomotic leakage in rectal cancer surgery: porcine model and multicenter retrospective cohort analysis. Ann Gastroenterol Surg 2021;6:256–64.
- [15] Mazaki J, Katsumata K, Ohno Y, et al. A novel predictive model for anastomotic leakage in colorectal cancer using auto-artificial intelligence. Anticancer Res 2021;41:5821–5.
- [16] Mazaki J, Katsumata K, Ishizaki T, *et al.* Effectiveness of a new triple-row circular stapler in reducing the risk of colorectal anastomotic leakage. A historical control and propensity score-matched study. Medicine 2022;101:e29325.
- [17] Quero G, Fiorillo C, Menghi R, *et al.* Preliminary evaluation of two-row versus three-row circular staplers for colorectal anastomosis after rectal resection: a single-center retrospective analysis. Int J Colorectal Dis 2022;37:2501–10.
- [18] Folkesson J, Nilsson J, Påhlman L, et al. The circular stapling device as a risk factor for anastomotic leakage. Colorectal Dis 2004;6:275–9.
- [19] Catarci M, Ruffo G, Viola MG, et al. ERAS program adherence-institutionalization, major morbidity and anastomotic leakage after elective colorectal surgery: the iCral2 multicenter prospective study. Surg Endosc 2022;36:3965–84.
- [20] The Italian Colorectal Anastomotic Leakage (iCral) study group. Patientreported outcomes and return to intended oncologic therapy after colorectal enhanced recovery pathway: the iCral3 prospective study. Ann Surg Open 2023;4:e267.
- [21] Mathew G, Agha R. for the STROCSS Group. STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg 2021;96:106165.
- [22] Yao XI, Wang X, Speicher PJ, et al. Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. J Natl Cancer Inst 2017;109:djw323.
- [23] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–13.
- [24] Katayama H, Kurokawa Y, Nakamura K, et al. Extended Clavien–Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today 2016;46:668–85.
- [25] Rahbari NN, Weitz J, Hohenberger W, et al. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery 2010;147:339–51.
- [26] Hébert J, Eltonsy S, Gaudet J, et al. Incidence and risk factors for anastomotic bleeding in lower gastrointestinal surgery. BMC Res Notes 2019;12:378.
- [27] Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399–424.
- [28] Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55.

- [29] Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol 2006;163:1149–56.
- [30] Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150–61.
- [31] Rosenbaum, PR. The power of a sensitivity analysis and its limit. In: Rosenbaum PR, editor. Design of Observational Studies, 2nd ed. Springer Series in Statistics. Springer Nature; 2020:pp. 317–336.
- [32] Nagaoka T, Yamaguchi T, Nagasaki T, et al. Safety of small circular staplers in double stapling technique anastomosis for sigmoid colon and rectal cancer. Dis Colon Rectum 2021;64:937–45.
- [33] Kim JS, Cho SY, Min BS, et al. Risk factors for anastomotic leakage after laparoscopic intracorporeal colorectal anastomosis with a double stapling technique. J Am Coll Surg 2009;209:694–701.
- [34] Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009;122:114–20.
- [35] Ioannidis JPA, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet 2014;383:166–75.
- [36] Pommergaard HC, Gessler B, Burcharth J, et al. Preoperative risk factors for anastomotic leakage after resection for colorectal cancer: a systematic review and meta-analysis. Colorectal Dis 2014;16:662–71.
- [37] Meyer J, Naiken S, Christou N, *et al.* Reducing anastomotic leak in colorectal surgery: the old dogmas and the new challenges. World J Gastroenterol 2019;25:5017–25.
- [38] McKechnie T, Sharma S, Daniel R, et al. End-to-end versus end-to-side anastomosis for low anterior resection: a systematic review and metaanalysis of randomized controlled trials. Surgery 2021;170:397–404.
- [39] Hu MH, Huang RK, Zhao RS, *et al.* Does neoadjuvant therapy increase the incidence of anastomotic leakage after anterior resection for mid and low rectal cancer? A systematic review and meta-analysis. Colorectal Dis 2017;19:16–26.
- [40] Hollandsworth HM, Li K, Zhao B, et al. Robotic left-stapled total intracorporeal bowel anastomosis versus stapled partial extracorporeal anastomosis: operative technical description and outcomes. Surg Endosc 2022;36:3645–52.
- [41] Kryzauskas M, Bausys A, Degutyte AE, et al. Risk factors for anastomotic leakage and its impact on long-term survival in left-sided colorectal cancer surgery. World J Surg Onc 2020;18:205.
- [42] García-Granero E, Navarro F, Cerdán Santacruz C, et al. Individual surgeon is an independent risk factor for leak after double-stapled colorectal anastomosis: an institutional analysis of 800 patients. Surgery 2017;162:1006–16.
- [43] Kelly M, Bhangu A, Singh P, et al. Systematic review and meta-analysis of trainee versus expert surgeon-performed colorectal resection. BJS 2014;101:750–9.
- [44] Lange MM, Buunen M, van de Velde CJ, *et al*. Level of arterial ligation in rectal cancer surgery: low tie preferred over high tie. A review. Dis Colon Rectum 2008;51:1139–45.
- [45] Rondelli F, Pasculli A, De Rosa M, et al. Is routine splenic flexure mobilization always necessary in laparotomic or laparoscopic anterior rectal resection? A systematic review and comprehensive meta-analysis. Updates Surg 2021;73:1643–61.
- [46] Balciscueta Z, Uribe N, Caubet L, et al. Impact of the number of stapler firings on anastomotic leakage in laparoscopic rectal surgery: a systematic review and meta-analysis. Tech Coloproctol 2020;24:919–25.
- [47] Tang G, Du D, Tao J, et al. Effect of indocyanine green fluorescence angiography on anastomotic leakage in patients undergoing colorectal surgery: a meta-analysis of randomized controlled trials and propensityscore-matched studies. Front Surg 2022;9:815753.
- [48] Pla-Martí V, Martín-Arévalo J, Moro-Valdezate D, et al. Impact of the novel powered circular stapler on risk of anastomotic leakage in colorectal anastomosis: a propensity score-matched study. Tech Coloproctol 2021;25:279–84.